What is CTRL Therapeutics?
Founded in 2022 and headquartered in Toronto, Canada, CTRL Therapeutics is dedicated to developing next-generation therapies for solid tumors. The company's innovative approach centers on harnessing the therapeutic potential of cTRLs (chimeric targeting receptors) to unlock new treatment avenues for patients battling challenging cancers. This focus positions CTRL Therapeutics at the forefront of immuno-oncology research, aiming to address unmet needs in a critical area of medical science.
How much funding has CTRL Therapeutics raised?
CTRL Therapeutics has raised a total of $10M across 1 funding round:
Angel/Seed
$10M
Angel/Seed (2023): $10M with participation from General Catalyst, FACIT, and Health
Key Investors in CTRL Therapeutics
General Catalyst
General Catalyst operates as a venture capital firm focused on identifying and supporting transformational business opportunities across multiple sectors and stages. The firm deploys capital strategically to back entrepreneurs and management teams pursuing ambitious visions that reshape their respective industries.
FACIT
Undisclosed investor participating in the funding round.
Health
Undisclosed investor participating in the funding round.
What's next for CTRL Therapeutics?
With its recent major enterprise-level funding, CTRL Therapeutics is poised for accelerated growth and the advancement of its therapeutic pipeline. The substantial capital injection will likely fuel further research and development, clinical trials, and the scaling of operations. This investment signals strong confidence from backers in the company's technology and its potential to make a significant impact on solid tumor treatment, paving the way for future breakthroughs and market expansion.
See full CTRL Therapeutics company page
